Article
Kashiv BioSciences Reports Positive Topline Results For XOLAIR® Biosimilar Candidate ADL-018
On June 25, 2025, Kashiv BioSciences announced positive topline results from its confirmatory Phase 3 trial of ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), in patients with chronic spontaneous urticaria.
Goodwin Procter LLP